The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.
 
Victor Moreno
Consulting or Advisory Role - Puma Biotechnology
Travel, Accommodations, Expenses - Sanofi/Regeneron
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Maria Eugenia Olmedo Garcia
No Relationships to Disclose
 
Marta Gil-Martin
No Relationships to Disclose
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; Regeneron
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule (Inst); Bayer (Inst)
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Lee S. Rosen
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst)
 
Petra Rietschel
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Honoraria - Regeneron
 
Kosalai Kal Mohan
Employment - Regeneron
Stock and Other Ownership Interests - Agenus; Amicus Therapeutics; Bellicum Pharmaceuticals; Cel-Sci; Celldex; Gilead Sciences; Merck; Navidea; Newlink Genetics; Progenics; Sarepta Therapeutics; Soligenix; Sorrento Therapeutics; Veracyte
Travel, Accommodations, Expenses - Regeneron
 
Jingjin Li
Employment - Novartis; Regeneron
Stock and Other Ownership Interests - Novartis; Regeneron
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Merck; Regeneron
 
Tracey Rowlands
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - McGill University (I); Zonula, Inc (I)
 
Minjie Feng
Employment - Regeneron
Stock and Other Ownership Interests - Bayer
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Consulting or Advisory Role - Egenix
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)